Human SK-N-AS neuroblastoma and U-87MG glioblastoma cell lines were found to secrete relatively high levels of glial cell line-derived neurotrophic factor (GDNF). In response to growth factors, cytokines, and pharmacophores, the two cell lines differentially regulated GDNF release. A 24-hr exposure
Identification of differentially expressed proteins in human glioblastoma cell lines and tumors
✍ Scribed by Rulin Zhang; Tammy-Lynn Tremblay; Angela Mcdermid; Pierre Thibault; Danica Stanimirovic
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 408 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0894-1491
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
An in‐frame deletion of 801 bp in exons 2–7 (type III mutation) of the epidermal growth factor receptor (EGFR) is detected at high incidence in primary glioblastoma tumors. A proteomic approach was used to generate differential protein expression maps of fetal human astrocytes (FHA), human glioblastoma cell lines U87MG and U87MG expressing type III EGFR deletion (U87MGΔEGFR) that confers high malignancy to tumor cells. Two‐dimensional gel electrophoresis followed by in‐gel digestion of separated spots and protein identification by LC‐MS‐MS and matrix‐assisted laser desorption ionization time‐of‐flight mass spectrometry (MALDI‐TOF MS) identified 23 proteins expressed at higher levels or exclusively in FHA and 29 proteins expressed at higher levels or exclusively in U87MG cells. Three proteins, ubiquitin, cystatin B, and tissue transglutaminase (TTG), were upregulated in U87MGΔEGFR relative to U87MG. Four proteins highly expressed by U87MG cells, Hsp27, major vault protein, TTG, and cystatin B, were analyzed by Western blot, ELISA, or RT‐PCR in cell extracts and in tissue samples of glioblastoma multiforme (GBM; grade IV), low‐grade astrocytomas (grades I and II), and nonmalignant brain lesions. All four proteins were highly expressed in GBM tissues compared to nonmalignant brain. These proteins may be used as diagnostic or functional (e.g., multiple drug resistance, invasiveness) markers for glioblastoma tumors. GLIA 42:194–208, 2003. © 2003 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Previous studies have demonstrated a role for the fos gene in promoting malignant conversion of mouse skin tumors. In the study reported here, differential display was performed to identify fos- and jun-regulated genes that are differentially expressed during premalignant progression. Total RNA isol
Rapid advances in multimodality therapy have not significantly improved the overall 5-yr survival of oral cancer patients in the past two decades, thereby underscoring the need for molecular therapeutics. The development of new treatment strategies for more effective management of oral cancer requir